LICENSE AGREEMENTLicense Agreement • February 27th, 2018 • vTv Therapeutics Inc. • Pharmaceutical preparations • Delaware
This License Agreement (the “Agreement”) is made and entered into as of December 21, 2017 (the “Effective Date”) by and between Reneo Pharmaceuticals, Inc., a Delaware corporation (“Reneo”), having a place of business at 12730 High Bluff Drive, Suite 160, San Diego, CA 92130, USA, and vTv Therapeutics LLC, a limited liability company organized under the laws of Delaware (“vTv”), with its principal place of business at 4170 Mendenhall Oaks Pkwy, High Point, NC 27265. Reneo and vTv are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AGREEMENT BY AND BETWEEN HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO., LTD. AND vTv THERAPEUTICS LLC DATED AS OF DECEMBER 21, 2017License Agreement • February 27th, 2018 • vTv Therapeutics Inc. • Pharmaceutical preparations • New York
WHEREAS, vTv has developed or obtained rights to vTv Know-How, vTv Patent Rights and the Compound, TTP273, which is a glucagon-like peptide-1 receptor agonist (each as defined below); and
FIRST amendment of VENTURE LOAN AND SECURITY AGREEMENT AND CONSENTVenture Loan and Security Agreement and Consent • February 27th, 2018 • vTv Therapeutics Inc. • Pharmaceutical preparations • New York
This FIRST AMENDMENT OF VENTURE LOAN AND SECURITY AGREEMENT AND CONSENT (this “Agreement”), dated as of December 20, 2017, is entered into by and among vTv THERAPEUTICS INC. (“VTV INC”), vTv THERAPEUTICS LLC (“VTV LLC” and collectively with VTV INC, “Co-Borrowers”), HORIZON CREDIT II LLC (“HCII”), as assignee of HORIZON TECHNOLOGY FINANCE CORPORATION (“Horizon”), SILICON VALLEY BANK, (“SVB”, and collectively with HCII “Lenders”) and Horizon as Collateral Agent.
